BioCentury
ARTICLE | Clinical News

Sage climbs on Phase II MDD readout

February 13, 2017 9:59 PM UTC

Sage Therapeutics Inc. (NASDAQ:SAGE) Sage jumped $5.57 (12%) to $52.99 on Monday after it said SAGE-217 significantly reduced depression ratings in the first part of a Phase II trial to treat severe major depressive disorder in adults. The results met criteria for starting the trial's placebo-controlled second part, Sage said.

Among 13 patients in the trial's open-label first part, Sage said once-daily oral SAGE-217 significantly reduced mean Hamilton Rating Scale for Depression (HAM-D) total scores from a baseline of 27.2 to 7.3 at day 15 (p<0.0001). The primary endpoint measured safety and tolerability. Sage said SAGE-217 was generally well tolerated with no serious adverse events or discontinuations...

BCIQ Company Profiles

Sage Therapeutics Inc.

BCIQ Target Profiles

GABA A receptor